Autoimmune diseases (ADs) is a condition in which immune system mistakenly attacks the body’s own tissues/cells. Over 80 types of ADs have been identified in humans and ADs can occur in any part of the body (see the left diagram below). The incidence of ADs is increasing rapidly worldwide in recent years due to the environmental changes. ADs are now the 4^th largest cause of disability in women and the 8^th leading cause of death for women between ages 15-64.

Current in vitro diagnostics (IVD) of ADs mainly depend on the detection of circulating auto-antibodies specifically associated with certain ADs (see the right diagram below). By generating autoantigen-based immunoassays, corresponding autoantibodies can be determined in the blood stream of patients via the autoantigen-autoantibody interaction.

Multiple detection methods, such as ELISA, immunofluorescence test and radio-immunoassay, have been applied for the diagnosis of ADs. However, there are several major challenges remained:

The sensitivity and accuracy of the majority of existing diagnostic kits is very low, as the auto-antigens used for these assays are mainly produced in E. coli cells, therefore do not preserve proper epitopes for efficient recognition of autoantibodies.

Low throughput for screening for multiple ADs whereas many ADs are inter-related.

Detection of autoantibodies can not provide pathogenic insights.

We have developed a comprehensive platform ranging from the discovery of novel autoantibodies and biomarkers for ADs, production of high-quality recombinant autoantigens with structures resembling to native protein in vivo, to development and clinical validation of highly sensitive and specific immunoassays for autoantibodies and new biomarkers. Our unique tech platform has significantly increased the detection rate and specificity for multiple major ADs.

• By far, we have developed a series of ready-to-use diagnostic kits and high-quality raw materials for ADs:
• >30 high-quality recombinant autoantigens using insect and mammalian cell expression systems;
• 5 highly sensitive and specific ELISA kits;
• 6 types of membrane-based test strips for 7 major ADs.
• All the kits and raw materials have been validated in >300 clinical samples and been proven to show excellent batch-to-batch repeatability, specificity and accuracy.

See our products as follows: